Proposal written abstract report
- 1. Clinical and Pharmacological Trials in humans for the diagnosis of Alzheimer’s disease Alzheimer’s disease is nowadays the sixth of memory loss of recent events, such as major cause of death in the United States. It what a patient said to his daughter five has been estimated that more than 10 minutes ago. There are three major stages of percent of the population over 65 years old dementia in an Alzheimer patient’s life. The suffers from “mild” to “moderated” Amnesia stage, corresponding to a loss of dementia, and 4 to 5 percent suffer from mathematical and basic visual-motor severe dementia.But, what about the abilities.The Confusional stage, younger people? Clinical and Trial research corresponding to a continuing decline in are by far the most common types of studies cognitive functioning. Is the impairment of scientists and medicine professionals use in speaking and writing. The inability to order to diagnose the disease. Several comprehend sensorial stimuli is also an clinical studies had shown a considerable effect of this stage. Finally, at the Dementia growth of people suffering Alzheimer’s stage, the patient is completely withdrawn disease during the middle stages of their life. and unresponsive. At this final stage the Most of that people have had a medical patient completely depends of nursing care. history of cardiovascular conditions. Cardiovascular conditions directly affect the Through a controlled research I will do both, development of Alzheimer’s disease. It has Clinical and Trial studies in order to been proven that Alzheimer uncontrolled compare which one is more efficient for the development is sometimes cause by that diagnosis of Alzheimer. Therefore, I will type of conditions, such as heart strokes, and make a comparison on the incidence of high risk blood pressure level. The purpose Alzheimer’s disease between the people that of this research is to prove that have had cardiovascular conditions against cardiovascular diseases directly affects the those who had not. development of Alzheimer’s disease in Presenile dementia, best known as patients under the age of 65. Alzheimer's disease, will be the major topic This research will be based on both, to study on this research. The onset of senile Clinical and Pharmacological Trial studies, dementia is characterized by an impairment in order to make an efficiency comparison
- 2. between them. Clinical studies will consist going to be diversity among groups of of two groups. Each group will be formed of people exposed to different environmental a hundredth members. One half will be factors that could affect the experiment. All having a cardiovascular condition medical the participants of this Trial must sign a history, and the other half will not. The consent agreement, affirming the Clinical studies will be very simple. A understanding of the type of study and its patient will have to answer five, previously purpose. chosen questions, in a controlled time of five Since two different studies take part minutes. Then the patient will have to on this research, there are two expected answer another series of questions in the results. The first one is to prove same amount of time. After the ending of Pharmacological Trial studies are more the second group of questions, the health efficient on the diagnosis of Alzheimer’s professional will ask the first question of disease. However, common Clinical studies each group of questions. The diagnosis of are not completely accurate on the diagnosis dementia will be based on the patient’s process. The second one is to prove people ability to remember those questions and the with cardiovascular conditions are more ability to correctly answer them. likely to develop the disease before the age Trial studies will be a more complicated task of 65 years old. To prove drugs used for the to do. Trials will consist of four groups, each treatment of cardiovascular conditions group made out of 25 members. Two of negatively affect the development of those groups will be having a medical dementia in young patients is also one of my history on cardiovascular conditions, but expected results. they will be not receiving any kind of References treatment. The other groups will be having Feldman, Robert. Meyer, Jerrold. cardiovascular conditions, and will be Quenzer, Linda. 1997. Principles of Neuropsychopharmacology. Sinauer receiving a selected treatment. The purpose Associates, Inc., Publishers. Chapter of this Trial is to prove that drugs used to 18, part 2. Page 887. treat cardiovascular conditions directly affects the development of Alzheimer’s disease. Trial studies will be going to consist of four groups because in that way it is